MRK
Merck & Co., Inc.
NYSE · Healthcare · Drug Manufacturers - General · US
$146.76
−0.27%Aug 8, 2026, 23:00 UTC
Uniquity Bio appointed Jason Moore as senior vice president of regulatory and quality.
Source:Aug 7, 2026, 03:07 UTC
Merck & Co.'s Ebola vaccine and Gilead Sciences' antiviral drug are set for wider use in eastern Democratic Republic of Congo to combat the fastest-growing Ebola outbreak on record.
Source:Aug 6, 2026, 10:45 UTC
The U.S. FDA accepted Merck's supplemental Biologics License Application for ENFLONSIA (clesrovimab-cfor) to expand its RSV lower respiratory tract disease indication to include children under two years at increased risk for severe RSV through their second season.
Source:Aug 4, 2026, 23:40 UTC
McDonald's and Merck reported earnings that beat analyst expectations.
Source:Aug 4, 2026, 15:16 UTC
Merck incurred costs related to its acquisition of Turnstone Biologics, a leukemia drug developer, which impacted its full-year EPS guidance.
Source:Aug 4, 2026, 10:34 UTC
Merck incurred a charge related to its acquisition of Terns Pharmaceuticals, which affected its profit guidance.
Aug 3, 2026, 18:02 UTC
Merck & Co. presented its HIV treatment and prevention strategy at an investor event, highlighting Phase III results for a once-weekly oral HIV regimen and plans for a monthly oral PrEP candidate.
Source:Jul 31, 2026, 18:10 UTC
Merck acquired Terns Pharmaceuticals and Cidara Therapeutics to broaden its oncology and virology portfolios.
Source:Jul 31, 2026, 18:10 UTC
Merck launched subcutaneous Qlex, extending the lifecycle of Keytruda.
Source:Jul 31, 2026, 14:30 UTC
Rappta Therapeutics, founded by Goutham Narla, was acquired by Merck, which will develop its treatment for endometrial and lung cancer.
Source:Jul 31, 2026, 09:15 UTC
Universal Corporation Limited (UCL) of Kikuyu, Kenya, was selected by Merck as one of seven manufacturers worldwide to produce alimatravir, an experimental once-monthly HIV prevention pill, under a licensing agreement announced at the 26th International Aids Conference in Rio de Janeiro.
Source:Jul 29, 2026, 15:04 UTC
Merck announced its fourth-quarter 2026 dividend on July 29, 2026.
Source:Jul 27, 2026, 01:54 UTC
Aurobindo Pharma Ltd has entered into a non-exclusive voluntary licensing agreement with MSD (Merck & Co., Inc.) for an HIV drug.
Source:Jul 24, 2026, 19:38 UTC
Qnity Electronics, Inc. appointed Katherine (Kate) Dei Cas as President of its Semiconductor Technologies business segment, effective August 3.
Source:Jul 24, 2026, 10:45 UTC
Merck has licensed its experimental oral HIV drug to generic manufacturers in 129 countries.
Jul 21, 2026, 14:00 UTC
Gilead Sciences and Merck & Co. announced phase 3 clinical trial results for their two-drug combination lenacapavir and islatravir, positioning it as the first complete weekly oral HIV treatment.
Source:Jul 20, 2026, 01:05 UTC
Merck Animal Health's needle-free intradermal vaccine Porcilis® M Hyo ID ONCE® received approval from China's Ministry of Agriculture and Rural Affairs for the prevention of disease caused by Mycoplasma hyopneumoniae infection in pigs.
Source:Jul 17, 2026, 00:00 UTC
GSK discontinues development of camlipixant, an experimental chronic cough medicine, after mixed Phase 3 data.
Jul 16, 2026, 17:49 UTC
The U.S. Food and Drug Administration approved Merck's first-of-its-kind cholesterol-lowering pill Lipfendra for high-risk patients.
Jul 16, 2026, 11:30 UTC
Medicus Pharma received positive FDA feedback and central IRB approval for its optimized Phase 2 study of Teverelix in acute urinary retention.
Jul 15, 2026, 17:25 UTC
Merck & Co. released topline data from the Phase 3 KEYNOTE‑C93 trial showing Keytruda outperforms chemotherapy in advanced endometrial cancer.
Source:Jul 15, 2026, 07:45 UTC
Kelun-Biotech announced that its Phase 3 clinical study (OptiTROP-Lung06) of sac-TMT combined with Keytruda for first-line treatment of PD-L1-negative advanced or metastatic NSCLC met its primary endpoint.
Source:Jul 13, 2026, 17:00 UTC
Cosmos Health entered into a five-year partnership with Libytec to commercialize DIABIT-IS X in Greece, with Cosmos Health supplying the product and Libytec handling distribution and promotion.
Source:Jul 10, 2026, 16:15 UTC
The U.S. House Select Committee on the Chinese Communist Party launched a bipartisan investigation into five major American pharmaceutical companies over clinical trials conducted in China, including at hospitals linked to the People's Liberation Army and in Xinjiang province, sending letters demanding records by July 17.
Jul 2, 2026, 02:30 UTC
Merck Animal Health will launch Senstan® in China.
Source:Jun 9, 2026, 20:36 UTC
Gilead and Merck report positive phase III results for once-weekly HIV regimen islatravir/lenacapavir.
Source: